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Accumulating evidence indicates that altered miRNA
expression is crucially involved in lung cancer develop-
ment, though scant information is available regarding how
MYC, an archetypical oncogene, is regulated by miRNAs,
especially via a mechanism involving MYC cofactors.
Although various oncogenes have thus far been identiﬁed
to be altered in various types of lung cancer, MYC is among
the most frequently ampliﬁed and overexpressed. The
MYC gene encodes a transcription factor that regulates a
wide variety of genes involved in control of cell growth,
proliferation, and apoptotic cell death. The transcriptional
activity of MYC is tightly controlled for proper transcrip-
tional regulation through various mechanisms, which
include MYC expression itself at both transcriptional and
posttranscriptional levels, as well as its interaction with
cofactors that functionally cooperate with MYC. Unfortu-
nately, very little is known thus far about how MYC is
regulated by miRNAs in lung cancer cells, especially via
the latter mechanism involving MYC cofactors.
In this study, we attempted to identify miRNAs
involved in regulation of MYC transcriptional activity in
lung cancer. To this end, we utilized an integrative
approach with combinatorial usage of miRNA and mRNA
expression proﬁle datasets of patient tumor tissues, as
well as those of MYC-inducible cell lines in vitro. Our re-
sults allowed us to identify multiple miRNAs reported as
either directly downstream or upstream of MYC, sup-
porting the robustness of our strategy. The former ex-
amples included the miR-17-92 cluster, miR-22, miR-26a,
miR-30a-3p, and miR-30e-3p, all of which were previ-
ously shown to be under MYC-mediated transcriptionalregulation, while the latter instances were comprised of
let-7, miR-34a and miR-24, which have been reported to
directly repress MYC expression via binding to a target
site at the 3’UTR of MYC. Intriguingly, our integrative
approach also led us to identify miR-342-3p, which we
found to be amiRNA indirectly regulatingMYC activity via
direct inhibition of E2F1, a MYC-cooperating transcrip-
tion factor. Furthermore, miR-342-3p module activity,
which we deﬁned as a gene set reﬂecting the experi-
mentally substantiated inﬂuence ofmiR-342-3p onmRNA
expression, was found to be inversely correlated with
MYC activity reﬂected by MYC module activity in 3 inde-
pendent datasets of lung adenocarcinoma patients. Our
present ﬁndings also clearly demonstrate that miR-342-
3p plays important roles to inhibit cell cycle progression
and proliferation in lung adenocarcinoma cell lines.
Taken together, our integrative approach appears to
be useful to elucidate inter-regulatory relationships be-
tween miRNAs and protein coding genes of interest, even
those present in patient tumor tissues, which remains a
challenge to better understand the pathogenesis of this
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Immunoproteasome are a specialized form of multi-
subunit complexes called proteasome that degrade
intracellular proteins through the ubiquitin-proteasome
pathway. It can generate peptides with high speciﬁcity
for binding onto MHC class I molecules, hence a
suitable candidate for CD8þ T cell mediated cytotoxic
responses. The expression of the immunoproteasome
and its impact on antigen presentation in tumors of
epithelial origin is not well established. We have
investigated the constitutive and induced expression
patterns of immunoproteasome subunits in non-small
cell lung cancer (NSCLC) and their consequence on
antigen presentation. We also assessed the impact of
immunoproteasome expression on survival in early
stage NSCLC.
